JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kostakoglu, L.
Right arrow Articles by Goldsmith, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kostakoglu, L.
Right arrow Articles by Goldsmith, S. J.
Journal of Nuclear Medicine Vol. 43 No. 8 1018-1027
© 2002 by Society of Nuclear Medicine

Clinical Investigations

PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease

Lale Kostakoglu, MD1, Morton Coleman, MD2, John P. Leonard, MD2, Ichiei Kuji, MD1, Holly Zoe1 and Stanley J. Goldsmith, MD1

1 Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York
2 Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York

Early identification of chemotherapy-refractory lymphoma patients provides a basis for alternative treatment strategies. Metabolic imaging with 18F-FDG PET offers functional tissue characterization that is useful for assessing response to therapy. Our objective was to determine the predictive value of 18F-FDG PET early during chemotherapy (after 1 cycle) and at the completion of chemotherapy for subsequent progression-free survival (PFS) in patients with aggressive non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD). Methods: 18F-FDG PET (dual-head coincidence camera with attenuation correction) was performed before and after 1 cycle of chemotherapy on 30 patients (17 NHL, 13 HD; mean age, 52.3 ± 16.0 y). For 23 of the 30 patients, 18F-FDG PET data were also obtained after the completion of chemotherapy. The patients had a median follow-up of 19 mo (range, 18–24 mo). Follow-up of PFS was compared between patients with positive and negative 18F-FDG PET results obtained after the first cycle of chemotherapy and at the completion of chemotherapy. Results: Positive 18F-FDG PET results obtained both after the first cycle and at the completion of therapy were associated with a shorter PFS (median, 5 and 0 mo, respectively) than were negative 18F-FDG PET results (PFS medians not reached). A statistically significant difference in PFS between positive and negative 18F-FDG PET results was obtained both after the first cycle and at the completion of chemotherapy (P <= 0.001). The PFS and 18F-FDG PET results obtained after the first cycle correlated better than those obtained after the completion of chemotherapy (r2 = 0.45 vs. 0.17). 18F-FDG PET had more false-negative results after the last cycle (6/17 cases, or 35%) than after the first cycle (2/13 cases, or 15%). Thus, 18F-FDG PET had greater sensitivity and positive predictive values after the first cycle (82% vs. 45.5% and 90% vs. 83%, respectively) than after the last cycle. Conclusion: 18F-FDG PET after 1 cycle of chemotherapy is predictive of 18-mo outcome in patients with aggressive NHL and HD and may earlier identify patients who would benefit from more intensive treatment programs.

Key Words: lymphoma • chemotherapy • posttherapy • 18F-FDG PET




This article has been cited by other articles:


Home page
 haematolHome page
C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
Haematologica, March 1, 2008; 93(3): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA, November 21, 2007; 298(19): 2289 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
J. Clin. Oncol., August 20, 2007; 25(24): 3746 - 3752.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence
A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer
J. Clin. Oncol., July 20, 2007; 25(21): 3116 - 3123.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al.
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
Haematologica, June 1, 2007; 92(6): 771 - 777.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al.
Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma
Haematologica, June 1, 2007; 92(6): 778 - 783.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend
Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT
J. Nucl. Med., May 1, 2007; 48(5): 744 - 751.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K Strobel, N. Schaefer, C Renner, P Veit-Haibach, D Husarik, A. Koma, and T. Hany
Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
Ann. Onc., April 1, 2007; 18(4): 658 - 664.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Brepoels, S. Stroobants, P. Vandenberghe, K. Spaepen, P. Dupont, J. Nuyts, G. Bormans, L. Mortelmans, G. Verhoef, and C. De Wolf-Peeters
Effect of Corticosteroids on 18F-FDG Uptake in Tumor Lesions After Chemotherapy
J. Nucl. Med., March 1, 2007; 48(3): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al.
Revised Response Criteria for Malignant Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. J. Dann, R. Bar-Shalom, A. Tamir, N. Haim, M. Ben-Shachar, I. Avivi, T. Zuckerman, M. Kirschbaum, O. Goor, D. Libster, et al.
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Blood, February 1, 2007; 109(3): 905 - 909.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng
Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease
J. Clin. Oncol., September 1, 2006; 24(25): 4116 - 4122.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. S. Jhanwar and D. J. Straus
The Role of PET in Lymphoma
J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, et al.
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
Ann. Onc., August 1, 2006; 17(8): 1296 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
M. E. Juweid
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 295 - 302.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hutchings, A. Loft, M. Hansen, L. M. Pedersen, T. Buhl, J. Jurlander, S. Buus, S. Keiding, F. D'Amore, A.-M. Boesen, et al.
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Blood, January 1, 2006; 107(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. J. Reinhardt, C. Herkel, C. Altehoefer, J. Finke, and E. Moser
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Ann. Onc., September 1, 2005; 16(9): 1524 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. G. Mikhaeel, M. Hutchings, P. A. Fields, M. J. O'Doherty, and A. R. Timothy
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
Ann. Onc., September 1, 2005; 16(9): 1514 - 1523.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Haioun, E. Itti, A. Rahmouni, P. Brice, J.-D. Rain, K. Belhadj, P. Gaulard, L. Garderet, E. Lepage, F. Reyes, et al.
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
Blood, August 15, 2005; 106(4): 1376 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid and B. D. Cheson
Role of Positron Emission Tomography in Lymphoma
J. Clin. Oncol., July 20, 2005; 23(21): 4577 - 4580.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Hutchings, N. G. Mikhaeel, P. A. Fields, T. Nunan, and A. R. Timothy
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
Ann. Onc., July 1, 2005; 16(7): 1160 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Sun, T. J. Mangner, J. M. Collins, O. Muzik, K. Douglas, and A. F. Shields
Imaging DNA Synthesis In Vivo with 18F-FMAU and PET
J. Nucl. Med., February 1, 2005; 46(2): 292 - 296.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. W. Sweetenham
Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease
Hematology, January 1, 2005; 2005(1): 252 - 259.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
RadioGraphics, January 1, 2005; 25(1): 191 - 207.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Yamane, O. Daimaru, S. Ito, K. Yoshiya, T. Nagata, S. Ito, and H. Uchida
Decreased 18F-FDG Uptake 1 Day After Initiation of Chemotherapy for Malignant Lymphomas
J. Nucl. Med., November 1, 2004; 45(11): 1838 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. C. Toner
Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use
J. Clin. Oncol., October 1, 2004; 22(19): 3842 - 3845.
[Full Text] [PDF]

Home page
 JCOHome page
S. J. Horning, E. Weller, K. Kim, J. D. Earle, M. J. O'Connell, T. M. Habermann, and J. H. Glick
Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484
J. Clin. Oncol., August 1, 2004; 22(15): 3032 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
N. P. Lenzo, G. Moschilla, and A. Patrikeos
Diffuse Splenic Metastases from Seminoma Visualized on FDG PET
Am. J. Roentgenol., August 1, 2004; 183(2): 525 - 527.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
R. M. Meyer, R. F. Ambinder, and S. Stroobants
Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
Hematology, January 1, 2004; 2004(1): 184 - 202.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Schoder, S. M. Larson, and H. W.D. Yeung
PET/CT in Oncology: Integration into Clinical Management of Lymphoma, Melanoma, and Gastrointestinal Malignancies
J. Nucl. Med., January 1, 2004; 45(90010): 72S - 81.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist, October 1, 2003; 8(5): 438 - 447.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Guay, M. Lepine, J. Verreault, and F. Benard
Prognostic Value of PET Using 18F-FDG in Hodgkin's Disease for Posttreatment Evaluation
J. Nucl. Med., August 1, 2003; 44(8): 1225 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Chesnay, E. Babin, J. M. Constans, D. Agostini, A. Bequignon, A. Regeasse, F. Sobrio, and S. Moreau
Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome
J. Nucl. Med., April 1, 2003; 44(4): 526 - 532.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
V. J. Lowe and G. A. Wiseman
Assessment of Lymphoma Therapy Using 18F-FDG PET
J. Nucl. Med., August 1, 2002; 43(8): 1028 - 1030.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.